Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With PraliaSubcutaneousInjection 60 mg Syringe Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for ...
Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With PraliaSubcutaneousInjection 60 mg Syringe -Medical Information Database Network-based Cohort Study- Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for ...
Rheumatoid Arthritis
Intervention name : PRALIA60mgSubcutaneousInjectionSyringe(denosumab) INN of the intervention : denosumab Dosage And administration of the intervention : For adults under normal conditions, 60 mg of denosumab (genetic recombination) is injected subcutaneously every six months. If bone erosion progression occurs when denosumab is injected once every 6 months, denosumab can be injected subcutaneously once every 3 months. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : PRALIA60mgSubcutaneousInjectionSyringe(denosumab) INN of the intervention : d ...